微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志

• 论文 • 上一篇    下一篇

紫杉醇联合化疗方案治疗晚期乳腺癌的临床观察

郑建华;   

  1. 广西浦北县人民医院;
  • 收稿日期:2010-03-25 修回日期:2010-03-25 出版日期:2010-03-25 发布日期:2010-03-25

Paclitaxel-combined chemotherapy in treating advanced breast cancer

ZHENG Jian-hua.   

  1. (People's Hospital of Pubei County,Guangxi 535300,China
  • Received:2010-03-25 Revised:2010-03-25 Online:2010-03-25 Published:2010-03-25

赞

被引次数

20

摘要： 目的观察紫杉醇和阿霉素(TA方案)与紫杉醇和顺铂(TP方案)治疗晚期乳腺癌的疗效和不良反应。方法35例转移性乳腺癌患者中既往未采用蒽环类药物治疗的19例采用紫杉醇联合阿霉素治疗(TA方案组);既往使用蒽环类药物治疗失败的16例以紫杉醇联合顺铂治疗(TP方案组)。观察两组疗效及副反应情况。结果35例均可评价疗效,TA方案组有效率为52.6%(10/19),中位缓解期8.6个月,中位生存期14.5月;TP方案组有效率为43.8%(7/16),中位缓解期7.8个月,中位生存期13.8月。两组疗效及缓解期、中位生存期差异均无统计学意义(P均>0.05)。主要毒性反应为白细胞减少、恶心呕吐和脱发等。结论紫杉醇联合化疗对晚期乳腺癌的疗效确切,毒性反应可以耐受,未出现变态反应。TA、TP方案组的疗效近似,可作为晚期乳腺癌一线化疗方案。

关键词: 紫杉醇, 阿霉素, 顺铂, 乳腺癌

Abstract: Objective To evaluate the efficacy and toxicity of Paclitaxel(PTX) combined with Adriamycin(ADM) or cisplatin(DDP) in treating advanced breast cancer.Methods Thirty-five patients with advanced breast cancer were treated with PTX 135mg/m2 on d1 plus ADM 40mg/m2 on d1 or DDP 30 mg/m2 on d1~3.One cycle included 21～28 days treatment and each patient was given 2 cycles at least.Results 35 patients were evaluated for clinical response.The response rate in TA group was 52.6%(10/19),in TP group was 43.8%(7/16).The median remission period of TA and TP group was 8.6 and 7.8 months respectively,while the median survival period of TA and TP group was 14.5 and 13.8 months respectively.The differences of efficacy and median response duration between the two groups were not significantly(P>0.05).Main side effects included leukopenia,gastroenteric reaction and alopecia.Conclusions Paclitaxel-combined chemotherapy is effective for treating advanced breast cancer.There is no significant difference between the two programs.Both programs can be used as the first-line treatment for advanced breast cancer.

Key words: Paclitaxel, Adriamycin, Cisplatin, Breast cancer